An Independent Reading Room for the Tirzepatide Trial Record

What This Site Is

Clinic Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide — the synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist studied across the SURPASS and SURMOUNT phase-3 programs. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word 'clinic' in our name describes our editorial orientation: this reading room approaches the tirzepatide literature through the lens of clinical programs — titration schedules, monitoring protocols, trial-measured outcomes, and the structured dose-escalation regimens that produced the SURPASS and SURMOUNT results. It is a framing, not a service. No consultation occurs here. No prescription is issued. No compound is sold.

The tirzepatide evidence base is among the most extensive in metabolic pharmacology: twelve phase-3 trials enrolling more than 20,000 participants, a cardiovascular outcome trial (SURPASS-CVOT, 13,299 participants), and foundational structural biology characterizing the molecular basis of dual incretin receptor agonism. This is a published record that merits a dedicated reading room. That is what this site is.

Editorial Scope and Standards

Every quantitative claim on this site traces to a numbered citation in the references and citations index. We do not invent citations. We do not write from inference when the primary literature exists. Where the evidence is limited — as in the switch-from-semaglutide retrospective study (n = 15) or the multi-society perioperative guidance (limited evidence base, authors' own acknowledgment) — we describe the scope and limitation explicitly.

Tirzepatide is an FDA-approved prescription drug. All clinical use requires physician supervision and a valid prescription. This site presents research summaries for informational and educational purposes only. The primary literature is accessible via the DOI and PubMed links in our references and citations.

This site does not link to vendors, compounding pharmacies, or commercial sources. It does not use affiliate links. It has no commercial relationship with any pharmaceutical manufacturer or distributor.

Contact and Corrections

Corrections to citation errors or factual inaccuracies are welcomed. Use the contact page to submit a correction with the specific citation or claim in question. If a study updates a finding documented here — for example, a new analysis of SURPASS-CVOT data or an updated meta-analysis on perioperative GLP-1 management — submissions with DOIs are reviewed for inclusion.

See frequently asked questions for the most common clinical questions about tirzepatide answered from the published record.